(Q44221518)

English

High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.

scientific article published in December 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Massimo Di Nicola

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

author name string

Tarella C

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Caracciolo D

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Zallio F

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Cuttica A

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Omedè P

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Bondesan P

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Magni M

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Matteucci P

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Gallamini A

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Pileri A

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Gianni AM

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

language of work or name

0 references

publication date

1 December 2002

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Bone Marrow Transplantation

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

30

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

725-732

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12439694%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703729

0 references

Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphom

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

The risk of tumor cell contamination in peripheral blood stem cell collections

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

21 January 2018

Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Mobilization and transplantation of peripheral blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired stem cell collection by consecutive courses of high-dose mobilizing chemotherapy using cyclophosphamide, etoposide, and G-CSF

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

CD34 counts to predict the adequate collection of peripheral blood progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leuk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of further attempts to mobilize CD34+ peripheral stem cells with alternative procedures after primary failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703729

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1703729

1 reference

https://api.fatcat.wiki/v0/release/wdyu2iurlvesnkszsvkslnaxwq

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_wdyu2iurlvesnkszsvkslnaxwq

1 reference

https://api.fatcat.wiki/v0/release/wdyu2iurlvesnkszsvkslnaxwq

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/wdyu2iurlvesnkszsvkslnaxwq

30 July 2022

based on heuristic

mapped directly with Wikidata item

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44221518&oldid=2108687546"